Search results
Results from the WOW.Com Content Network
The selloff in ABBV stock was always a bit overdramatic. The pharma has over 90 therapies under development , over half of them being in mid- to late-stage trials. AbbVie spent $12.8 billion on ...
The contrast between AbbVie's performance and that of the wider market was stark, as the bellwether S&P 500 (SNPINDEX: ^GSPC) sank by a relatively steep 1.5%. Why AbbVie Stock Popped While the ...
The great news is that AbbVie has seemingly done that with its new immunology drugs Rinvoq and Skyrizi. ... Today, AbbVie's dividend payout ratio is 61% of 2024 earnings. That leaves plenty of ...
A splashy recent acquisition by the company might not be panning out.
For reference, AbbVie's trailing 12-month revenue was $55.3 billion, so the growth of Skyrizi and Rinvoq represents a major addition to the top line that'll likely drive the stock upwards for ...
The drugmaker has convincingly laid to rest the biggest threat to its top line.
In the latest trading session, AbbVie (ABBV) closed at $104.64, marking a +1.77% move from the previous day.
Today's Research Daily features new research reports on 16 major stocks, including AbbVie Inc. (ABBV), PepsiCo, Inc. (PEP) and The Walt Disney Company (DIS).